Resources
Press Releases
Zeteo Biomedical Secures Global Patents for Nasal and Ophthalmic Drug Delivery Device Innovations
CEDAR PARK, TX – June 11, 2025 (SEND2PRESS NEWSWIRE) – Zeteo Biomedical, a privately held biomedical device company, today announced the issuance of new patents in the United States and European Union for its advanced drug delivery technologies. The patents, titled...
Zeteo Biomedical Introduces CygnusMR™ and CygnusSDX™ Delivery Devices for NasalAdministration of Dry Powder Drugs and Biologics
Innovative Needle-Free Nasal Powder Delivery Systems Enhance Drug and Vaccine Development Cedar Park, TX – 19 February 2025 – Zeteo Biomedical LLC today announced the launch of its ZTech-P CygnusMR™ and CygnusSDX™ delivery devices, designed for precise, metered-unit...
City of Cedar Park Celebrates Relocation of Zeteo Biomedical Highlighting the City’s commitment to life sciences industry
Date: January 23, 2025Contact: Dan Sousa, City of Cedar Park Community Affairs Assistant Director737-222-0098, daniel.sousa@cedarparktexas.gov Contact: Michael Snyder, Zeteo Biomedical Media Coordinator512-614-0144, zeteo@zeteobiomed.com The City of Cedar Park is...
Zeteo Biomedical Joins U.S. Government’s Rapid Response Partnership Vehicle (RRPV)
Zeteo Biomedical Joins U.S. Government’s Rapid Response Partnership Vehicle (RRPV) Zeteo’s needle-free nasal delivery systems offer scalable solutions for the swift distribution of vaccines and medical countermeasures worldwide. Pflugerville, TX – August 21, 2024 –...
Presentations
How an Enabling Technology Can Unlock Product Performance
Tim Sullivan is CEO of Zeteo Biomedical, a company dedicated to providing drug and biologic delivery systems. In this episode Tim shares with Pat Kothe of Mastering Medical Devices podcast about how an enabling technology effects the efficacy of treatment,...
SXSW GHSIW Conference – March 2022
Beyond The Bicep: Technology Platforms For Global Scale Packaging, Rapid Deployment and Self Administration Of Nasal Vaccines and Biomedical Countermeasures Timothy Sullivan, Founder and CEO of Zeteo Biomedical presents technology and a future vision for protecting...
Beyond the Bicep
Technology Platforms For Global Scale Packaging, Rapid Deployment and Self Administration Of Nasal Vaccines and Biomedical Countermeasures
The COVID-19 Vaccine (It’s Not a Shot in the Dark)
Vaccines have been around for quite a while, so why has the COVID-19 vaccine been such a hot-button topic? Why has the method of action, parameters for storage, and transportation been something so widely discussed? It’s great that this information is being provided...
Partners
The Nanovaccine Institute is a consortium of 70 researchers at 20 universities, research institutes, national laboratories, and companies, coordinated by Iowa State University. Our research is a transdisciplinary merger of expertise in immunology, nanotechnology, materials science, microbiology, neuroscience, cancer biology, gerontology, clinical science, and social science. We are developing nanovaccines and nanotherapeutics for respiratory infections, neural disorders, tropical diseases, cancer, aging, and veterinary diseases.